

EMA/122026/2014

## European Medicines Agency decision

P/0062/2014

of 7 March 2014

on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate ) (Tamiflu) (EMEA-000365-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0062/2014

of 7 March 2014

on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate ) (Tamiflu) (EMA-000365-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the European Medicines Agency's decision P/192/2009 issued on 2 October 2009, the decision P/29/2011 issued on 28 January 2011, and the decision P/0133/2013 issued on 7 June 2013,

Having regard to the application submitted by Roche Registration Ltd on 22 November 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 February 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for oseltamivir (phosphate ) (Tamiflu), powder for oral suspension, capsule, hard, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom.

Done at London, 14 February 2014

For the European Medicines Agency  
Guido Rasi  
Executive Director  
(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/745360/2013

## Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000365-PIP01-08-M06

### Scope of the application

**Active substance(s):**

Oseltamivir (phosphate )

**Invented name:**

Tamiflu

**Condition(s):**

Treatment and prevention of influenza

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Capsule, hard

Powder for oral suspension

**Route(s) of administration:**

Oral use

**Name / corporate name of the PIP applicant:**

Roche Registration Ltd

**Information about the authorised medicinal product:**

See Annex II



## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted to the European Medicines Agency on 22 November 2013 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/192/2009 issued on 2 October 2009, the decision P/29/2011 issued on 28 January 2011, and the decision P/0133/2013 issued on 7 June 2013.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 18 December 2013.

## Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 14 February 2014

On behalf of the Paediatric Committee  
Dr Dirk Mentzer, Chairman  
(Signature on file)

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan**

## 1. Waiver

Not applicable.

## 2. Paediatric Investigation Plan

### 2.1. Condition: treatment and prevention of influenza

#### 2.1.1. Indication(s) targeted by the PIP

Treatment and prevention of influenza in healthy and immunocompromised patients from birth to less than 18 years of age.

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

#### 2.1.3. Pharmaceutical form(s)

Hard capsules for oral use.

Powder for oral suspension for oral use.

#### 2.1.4. Measures

| Area         | Number of studies | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quality      | 0                 | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Non-clinical | 0                 | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Clinical     | 6                 | <p>Measure 1: Open-label, non-randomised, PK / PD and safety trial to evaluate oseltamivir in children less than 24 months of age with confirmed influenza infection.</p> <p>Measure 2: Randomized, double-blind, multi-centre, stratified trial to evaluate efficacy, safety, tolerability and resistance of oseltamivir conventional and high dose for the treatment of in immunocompromised paediatric patients from 1 year to less than 18 years of age (and in adults) with influenza.</p> <p>Measure 3: To simulate multi-dose administration of oseltamivir in immunocompromised children from birth to less than 18 year of age for treatment and prophylaxis of influenza.</p> <p>Measure 4: Open label, non-randomized, multiple dose PK / PD and safety trial of oseltamivir in the treatment of infants from birth to less than 12 months of age with confirmed influenza infection.</p> <p>Measure 5: Open label, randomized, two-arm multi-centre trial to evaluate pharmacokinetics and pharmacodynamics of two doses of oseltamivir in the treatment of influenza in immunocompromised paediatric patients from birth</p> |

|  |  |                                                                                                                                                                                                                                                                                                           |
|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  |  | <p>to less than 13 years of age</p> <p>Measure 6: Open label, prospective, multi-centre, observational study to evaluate safety, anti-viral activity and clinical outcomes of oseltamivir for treatment of immunocompromised children from at least 37 weeks of gestational age to less than 18 years</p> |
|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### 3. Follow-up, completion and deferral of the PIP

|                                                                                  |                  |
|----------------------------------------------------------------------------------|------------------|
| Concerns on potential long term safety issues in relation to paediatric use:     | Yes              |
| Date of completion of the paediatric investigation plan:                         | By December 2016 |
| Deferral for one or more studies contained in the paediatric investigation plan: | Yes              |

## **Annex II**

### **Information about the authorised medicinal product**

## **Condition(s) and authorised indication(s):**

### **1. Influenza**

Authorised indications:

#### **Treatment of influenza**

- In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see section 5.1).
- Tamiflu is indicated for the treatment of infants below 12 months of age during a pandemic influenza outbreak (see section 5.2).

#### **Prevention of influenza**

- Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.
- The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.

Tamiflu is indicated for post-exposure prevention of influenza in infants below 12 months of age during a pandemic influenza outbreak (see section 5.2).

## **Authorised pharmaceutical form(s):**

Capsule, hard; powder for oral suspension

## **Authorised route(s) of administration:**

Oral use